Gwo Xi Stem Cell Applied Technology Co. , Ltd

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

55

Website

www.gwoxi.com.tw

Country

Taiwan

Exchange

Taipei Exchange

Founded 2011

Gwo Xi Stem Cell Applied Technology Co. develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis

GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis

GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes. Founded in 2011, the company is based in Zhubei, Taiwan.

Key Stats

52-Week Range

NT$18.20NT$33.65

Beta0.07

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-0.84

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.